Hubbry Logo
search button
Sign in
Fominoben
Fominoben
Comunity Hub
arrow-down
History
arrow-down
starMore
arrow-down
bob

Bob

Have a question related to this hub?

bob

Alice

Got something to say related to this hub?
Share it here.

#general is a chat channel to discuss anything related to the hub.
Hubbry Logo
search button
Sign in
Fominoben
Community hub for the Wikipedia article
logoWikipedian hub
Welcome to the community hub built on top of the Fominoben Wikipedia article. Here, you can discuss, collect, and organize anything related to Fominoben. The purpose of the hub is to connect people, foste...
Add your contribution
Fominoben

Fominoben
Clinical data
Trade namesBroncomenal, Deronyl, Finaten, Noleptan, Oleptan, Terion, Tosifar, Tussirama[1]
Identifiers
  • N-[3-chloro-2-[[methyl-(2-morpholin-4-yl-2-oxoethyl)amino]methyl]phenyl]benzamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.038.135 Edit this at Wikidata
Chemical and physical data
FormulaC21H24ClN3O3
Molar mass401.89 g·mol−1
3D model (JSmol)
  • CN(CC1=C(C=CC=C1Cl)NC(=O)C2=CC=CC=C2)CC(=O)N3CCOCC3
  • InChI=1S/C21H24ClN3O3/c1-24(15-20(26)25-10-12-28-13-11-25)14-17-18(22)8-5-9-19(17)23-21(27)16-6-3-2-4-7-16/h2-9H,10-15H2,1H3,(H,23,27)
  • Key:KSNNEUZOAFRTDS-UHFFFAOYSA-N

Fominoben is an antitussive agent of the benzanilide class, formerly marketed under the name Noleptan.[2] It binds poorly to the sigma-1 receptor, a receptor activated by many other antitussives.[3] It is reported to have respiratory stimulant activity.[4] Other research has indicated it may be an agonist at the benzodiazepine site of the GABAA receptor.[5] It was introduced in Germany in 1973, in Italy in 1979, and in Japan in 1983.[6]

Adverse effects include appetite suppression, nausea, vomiting, insomnia, irritability, and hallucinations. Rarer side effects include somnolence, dizziness, dry mouth, blurred vision, and urticaria.[7]

References

[edit]
  1. ^ Swiss Pharmaceutial Society, ed. (January 2000). Index Nominum 2000: International Drug Directory. Taylor & Francis. p. 470. ISBN 978-3-88763-075-1.
  2. ^ "FOMINOBEN". NCATS Inxight: Drugs. Retrieved March 25, 2021.
  3. ^ Musacchio JM, Klein M (June 1988). "Dextromethorphan binding sites in the guinea pig brain". Cellular and Molecular Neurobiology. 8 (2): 149–56. doi:10.1007/BF00711241. PMC 11567495. PMID 3044591. S2CID 33844132.
  4. ^ Sasaki T, Sugiyama M, Sasaki H, Suzuki S, Takishima T (1985). "Effects of the antitussive fominoben (PB89) on hypoxia in chronic obstructive lung disease: comparison with dextromethorphan using a double-blind method". The Journal of International Medical Research. 13 (2): 96–101. doi:10.1177/030006058501300204. PMID 3158563. S2CID 30176251.
  5. ^ Crawley JN, Blumstein LK, Baldino F (January 1984). "Anxiolytic-like properties of fominoben". European Journal of Pharmacology. 97 (3–4): 277–81. doi:10.1016/0014-2999(84)90460-6. PMID 6142823.
  6. ^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 1705–7. ISBN 978-0-8155-1856-3.
  7. ^ Martín AV (2004). "Tratamiento sintomático de la tos y del resfriado común". Farmacología clínica y terapéutica médica. McGraw-Hill/Interamericana. p. 260. ISBN 9788448604271.